Pureos Bioventures invests in biotech companies advancing innovative treatments for severe diseases, with a focus on next-generation biological drugs and drug formats. The firm supports high-potential teams with development programs aimed at improving patient outcomes through transformative therapies.
Preferred startup development maturity for initial funding deployment.
Biotech companies developing innovative therapeutics, particularly next-generation biological drugs, antibody-drug conjugates (ADCs), gene therapies, and precision monoclonal antibodies for severe diseases.
Core thematic spaces, technologies, and target market segments of interest.
Standard financial allocation per investment round.
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...